On August 31, 2020, Petzer, Andreas L.; Sperr, Wolfgang R.; Buxhofer-Ausch, Veronika; Sliwa, Thamer; Schmidt, Stefan; Greil, Richard; Woelfler, Albert; Pichler, Petra; Dormann, Clemens; Burgstaller, Sonja; Tinchon, Christoph; Lang, Alois; Goebel, Florian; Uthman, Shanow; Muenchmeier, Niklas; Valent, Peter published an article.COA of Formula: C26H29Cl2N5O3 The title of the article was A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting – R-Effect study. And the article contained the following:
Methods: The Retrospective Evaluation of Early response in CML for long-term Treatment outcome (R-Effect), a multicenter, retrospective chart review, documented patients with newly diagnosed CML-CP starting first-line TKI therapy in routine clin. practice. The primary aim was to assess the 5-yr overall survival rate. Results: Of the 211 patients from 12 centers across Austria (Jan. 2004-May 2010), 176 (median age, 56 years) were included in the anal. All patients received first-line therapy with imatinib. Overall, 136 patients (77.3%) achieved ETR (ETR+ group), whereas 40 (22.7%) did not reach ETR (ETR- group). The ETR+ group had higher 5-yr overall survival (92.5% vs. 77.5%, P = 0.018) and progression-free survival (95.6% vs. 87.5%, P = 0.06) rates compared with the ETR- group. As expected, more patients in the ETR- group were switched to another TKI. At the last contact, 120 patients were still on imatinib and 44 had switched to another TKI (25 to nilotinib, 15 to dasatinib, and 4 to bosutinib). Conclusion: The data are in line with randomized trials demonstrating that ETR is associated with improved survival and thus confirmed these results in patients treated in daily clin. routine. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3
The Article related to chronic myeloid leukemia therapy, chronic myeloiud leukemia, chronic phase, clinical routine, retrospective evaluation, tyrosine kinase inhibitors, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.COA of Formula: C26H29Cl2N5O3
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics